HCPLive

Healthcare Expenditure Has Slowed in the US

WEDNESDAY, July 2, 2014 (HealthDay News) -- The growth in US healthcare expenditure has slowed in recent years, coming some way toward closing the gap with other countries of the Organisation for Economic Co-operation and Development (OECD), according to an article in the health of Americans series published online July 1 in The Lancet.

Noting that healthcare expenditure growth has slowed dramatically in the United States in recent years, Luca Lorenzoni, from the OECD in Paris, and colleagues reviewed expenditure trends and key policies in the United States and five other high-spending OECD countries since 2000.

The authors note that much of the difference between the United States and other high-spending counties can be explained by higher health-sector prices, and that price dynamics are mainly responsible for the expenditure growth slowdown. Expenditure growth was similar in the United States and in other counties, although other countries did not face the same challenges in health coverage and could draw from a broader set of policies to control expenditure. Some of the factors responsible for the slowdown in health care expenditure included increasing rate of generic drug use, a shift from inpatient to outpatient hospital care, and price control measures.

"Tightening Medicare and Medicaid price controls on plans and providers, and leveraging the scale of the public programs to increase efficiency in financing and care delivery, might prevent a future economic recovery from offsetting the slowdown in health sector prices and expenditure growth," the authors write.

Full Text (subscription or payment may be required)

Copyright © 2014 HealthDay. All rights reserved.

Most Popular

Recommended Reading

Researchers foresee new, effective Ebola treatments in the future due to a promising discovery in the deadly disease’s replication process.
A drug normally used to treat hypertension reduced the symptoms of multiple sclerosis in mice models of the disease.
Young leukemia patients are at risk for peripheral neuropathy due to an inherited gene variation, according to research published in JAMA.
The signs and symptoms of rheumatoid arthritis were improved at 3 months after various doses of the JAK 3 inhibitor decernotinib were administered.
$vAR$